Previous 10 | Next 10 |
home / stock / mrvff / mrvff news
- Blexten Canadian Prescriptions Increased 27% Quarter-Over-Prior Year Quarter- - Suvexx Canadian Prescriptions Increased 86% Quarter-Over- Prior Year Quarter – Miravo to Host Conference Call/Audio Webcast November 14th at 11:00 a.m. ET ...
The following slide deck was published by Nuvo Pharmaceuticals Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Nuvo Pharmaceuticals Inc. 2022 Q2 - Results - Earnings Call Presentation
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Anthony Snow to its Board of Directors (Board)...
Nuvo Pharmaceuticals Inc. (MRVFF) Q2 2022 Earnings Conference Call August 15, 2022 11:00 AM ET Company Participants Jesse Ledger - President and Chief Executive Officer Mary-Jane Burkett - Vice President and Chief Financial Officer Conference Call Participants ...
Nuvo Pharmaceuticals press release ( OTCQX:MRVFF ): Q2 Net Income was C$18.3M Revenue of C$20.9M (+5.6% Y/Y). As at June 30, 2022, cash and cash equivalents were $28.6M. For further details see: Nuvo Pharmaceuticals reports Q2 results
- Blexten Canadian Prescriptions Increased 17% Year-Over-Year - - Suvexx Canadian Prescriptions Increased 85% Year-Over-Year - - Plans to Wind-Down Manufacturing Facility in Varennes, Québec - Miravo to Host Conference Call/Audio Webcast Augu...
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its second quarter 2022 financial results ...
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Dale MacCandlish Weil to its Board of Director...
Nuvo Pharmaceuticals press release (OTCQX:MRVFF): Q1 GAAP EPS of $2M. Revenue of $15.75M. For further details see: Nuvo Pharmaceuticals net income of $2M, revenue of $15.75M
- Blexten Canadian Prescriptions Increased 21% Year-Over-Year - - Suvexx Canadian Prescriptions Increased 120% Year-Over-Year - Miravo to Hold Virtual Annual Meeting May 16th at 9:00 a.m. ET Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo He...
News, Short Squeeze, Breakout and More Instantly...
Nuvo Pharmaceuticals Inc Company Name:
MRVFF Stock Symbol:
OTCMKTS Market:
Nuvo Pharmaceuticals Inc (MRVFF) is expected to report for Q4 2022
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“ Miravo ” or the “ Company ”) is pleased to announce that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving its previously announ...
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“ Miravo ” or the “ Company ”) is pleased to announce that, at today’s special meeting of shareholders (the “ Meeting ”), its shareholders (“ Shareho...